Pediatric Cancer
Conditions
Keywords
Chemotherapy induced peripheral neuropathy, Pediatric Chemotherapy-Induced Neuropathy, Pediatric oncology, Psychometrics, Validation
Brief summary
The goal of this study was to conduct a cross-cultural adaptation of the P-CIN into the Chinese context, assess its psychometric properties, and determine the cut-off value of CIPN among Chinese pediatric oncology patients. Participants provided demographic and clinical characteristics, and complete the translated P-CIN, Wong-baker FACES Pain Rating scale for pain, and Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module for quality of life.
Detailed description
A methodological, descriptive study was conducted.
Interventions
None listed
Sponsors
Shanghai Children's Medical Center
Shenzhen Children's Hospital
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
The Hong Kong Polytechnic University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* (1) 6 to 18 years of age * (2) were diagnosed with cancer * (3) had received or were currently receiving neurotoxic chemotherapy drugs (e.g., Vincristine, Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Ixabepilone, Bortezomib, Thalidomide) * (4) were able to communicate, read, and write in Chinese without significant hearing and vision problems to ensure they understood the P-CIN.
Exclusion criteria
* (1) had a diagnosis of cancer in the central nervous system (CNS) cancer, cancer relapse or secondary cancer * (2) in the terminal stage * (3) planned to receive multiple cancer treatment (e.g., radiotherapy and immunotherapy) * (4) suffered from other neuromuscular diseases (e.g., traumatic brain injury and cerebral palsy) * (5) had a developmental deficit (e.g., Down's syndrome and other chromosomal disorders) * (6) have suffered from psychiatric diseases or used antipsychotic drugs * (7) had peripheral neuropathy symptoms caused by diabetes, genetic diseases, spinal cord injury, or alcoholism, or * (8) had other neuromuscular disorders (e.g., traumatic brain injury, cerebral palsy).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pediatric chemotherapy-induced peripheral neuropathy (P-CIN) scale | Baseline | For measuring participants' peripheral neuropathy induced by chemotherapy. The total score ranges from 0 to 65 with higher scores indicating more severe chemotherpay induced peripheral neuropathy. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Wong-baker Faces Pain Rating scale | Baseline | For measuring participants' pain related to chemotherpay induced peripheral neuropathy.This scale contains six faces with increasing degree of pain from left to right, where each face is rated on a scale of 10, in which 0 indicates no hurt, 2 indicates little bit hurts, 4 indicates little more hurts, 6 indicates even more hurts, 8 indicated a whole lot of hurts, and 10 indicated the worst hurts. higher scores indicating more severe pain. |
| Chinese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module | Baseline | To assess the participants' quality of life. The participants rated how frequently a particular problem occurred in the past month, using a three-point Likert scale (0 = Not at all, 2 = Sometimes, 4 = A lot) for children 5-7 years old and a five-point Likert scale (0 = Never, 1=Almost never, 2=sometimes, 3=often, 4 = Almost always) for children of 8-18 years old and for the parents of patients of all ages. Each item score will be reversely scored and then linearly transformed into 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). The scale score is the average of the total item scores, with higher scores representing better quality of life. |
| Clinician diagnosis of pediatric CIPN | Baseline | To ascertain the clinical diagnosis of CIPN in participants. The clinical diagnosis of CIPN could be made if the results of the nerve conduction study are abnormal, with a score of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ≥ 2 after the clinical consultation with a pediatric neurologist on the chemotherapeutic drugs used, cumulative doses, and clinical characteristics and time course of the CIPN symptoms. NCI-CTCAE items including five items: peripheral sensory neuropathy, peripheral motor neuropathy, constipation, diarrhea, and neuralgia. The sum score for the five NCI-CTCAE items was between 0 and 17. |
Countries
Hong Kong
Outcome results
None listed